ClinicalTrials.gg
WithdrawnNCT05982522Updated Mar 27, 2026

IN10018 Combination Therapy in Previously-treated Solid Tumors

A Phase 1/2 interventional study of IN10018 and Nab-paclitaxel in Solid Tumor, sponsored by InxMed (Shanghai) Co., Ltd.. Withdrawn. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by InxMed (Shanghai) Co., Ltd. · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Sponsor decided for withdraw.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a phase Ib/II, randomized, open-label, multicenter clinical trial to evaluate the antitumor activities, safety, tolerability and pharmacokinetics (PK) of IN10018 in combination with taxane and anti-PD-1/L1 monoclonal antibody in patients with locally advanced or metastatic solid tumors who have failed in or been intolerant to at least one line of standard therapy. This study will be firstly carried out in previously-treated non-small cell lung cancer (NSCLC) population,

Read the detailed description

This study consists of 2 parts: 1) Phase Ib-Dose Confirmation part: To assess the safety and recommended phase II dose (RP2D) of IN10018 in combination with taxane (nab-paclitaxel is proposed) and anti-PD-1/L1 monoclonal antibody (Tislelizumab is proposed) in previously-treated solid tumors. 2) Phase II-Dose Expansion part: To assess the antitumor efficacy and safety of IN10018+nab-paclitaxel+Tislelizumab as compared to nab-paclitaxel+Tislelizumab in previously-treated solid tumors. This study will be firstly carried out in previously-treated NSCLC population, and after getting enough efficacy and safety data of IN10018+nab-paclitaxel+Tislelizumab in NSCLC population and also taken into consideration of disease background of other specific solid tumors, sponsor will decide if to expand the treatment regimen into other solid tumors.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

InxMed (Shanghai) Co., Ltd. is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18-75 years old at the time of signing .
  2. Be able to understand and be willing to sign informed consent.
  3. or cytologically confirmed NSCLC, which is not suitable for locallly radical therapy.

    Note: Subjects should have received prior platinum-based doublet chemotherapy and /L1-based systemic therapy and failed in treatment.

  4. Subjects who have failed in 1- to 2 prior lines of standard systemic therapy.
  5. Has at least one measurable tumor lesion per 1.1.
  6. Has an performance status of 0 or 1.
  7. Estimated is more than 3 months.
  8. Has adequate organ function.
  9. AEs due to prior antitumor therapy must be recovered to ≤ Grade 1 ( v5.0) or a steady state as assessed by investigators
  10. Subjects (male and female) with must agree to use during the treatment phase and through 3 months after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Previously documented EGFR, ALK and ROS1 mutation.
  2. Have received chemotherapy, biological therapy, endocrine therapy, immunotherapy and other antitumor drugs within 4 weeks prior to the first dose of study treatment.
  3. Have received other antitumor drugs or treatments within 4 weeks prior to the first dose of study treatment.
  4. Have received radiotherapy within 14 days prior to the first dose of study treatment.
  5. Have had haematopoietic stem cell transplantation or organ transplantation.
  6. History of disease within the past 2 years.
  7. Have an immunodeficiency disorder or have received systemic therapy (prednisone or equivalent corticosteroid > 10 mg/day) or other within 7 days prior to the first dose of study treatment.
  8. Currently have interstitial pneumonitis.
  9. Have had FAK inhibitors treatment.
  10. Have received prior nab-paclitaxel treatment and the first documented disease progression/recurrence is within 6 months since the last dose of nab-paclitaxel treatment.
  11. other than the study disease within 3 years prior to the first dose of study treatment.
  12. Active central nervous system (CNS) and/or carcinogenic meningitis.
  13. Has a history of severe cardiovascular or cerebrovascular diseases within 6 months prior to the first dose.
  14. Pleural, pericardial or abdominal effusion that are clinically symptomatic and require puncture or drainage.
  15. Any active infection requiring systemic therapy within 14 days prior to the first dose of study treatment.
  16. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study. Note: Subjects who have experienced Grade ≥ 3 immuno-related AEs (irAEs) during prior immunotherapy will not be enrolled.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Experimental Group

    IN10018 + nab-paclitaxel + Tislelizumab in previously-treated NSCLC

    Drug: IN10018 · Drug: Nab-paclitaxel · Drug: Tislelizumab

  • Active comparator
    Control Group

    Nab-paclitaxel + Tislelizumab in previously-treated NSCLC

    Drug: Nab-paclitaxel · Drug: Tislelizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Recommended phase II dose (RP2D) of IN10018 in combination with nab-paclitaxel and Tislelizumab

    Evaluate the number of patients with dose-limited toxicities (DLTs); Determine the RP2D of IN10018 in combination with nab-paclitaxel and Tislelizumab.

    Time frame: 3 years

  2. Objective response rate (ORR) of IN10018+nab-paclitaxel+Tislelizumab as compared to nab-paclitaxel+Tislelizumab in previously-treated solid tumors per blinded independent central review (BICR) based on RECIST 1.1

    Defined as the proportion of subjects with complete response (CR) or partial response (PR)

    Time frame: 3 years

Secondary outcomes

  1. Progression-free survival (PFS) of IN10018+nab-paclitaxel+Tislelizumab as compared to nab-paclitaxel+Tislelizumab in previously-treated solid tumors per BICR and investigators based on RECIST 1.1

    Defined as the time from randomization to first documentation of disease progression or to death due to any cause, whichever comes first.

    Time frame: 3 years

  2. Duration of objective response (DOR) of IN10018+nab-paclitaxel+Tislelizumab as compared to nab-paclitaxel+Tislelizumab in previously-treated solid tumors per BICR and investigators based on RECIST 1.1

    Defined as the time from start of the first documentation of CR or PR to the first documentation of disease progression or to death due to any cause, whichever comes first.

    Time frame: 3 years

  3. Disease Control Rate (DCR) of IN10018+nab-paclitaxel+Tislelizumab as compared to nab-paclitaxel+Tislelizumab in previously-treated solid tumors per BICR and investigators based on RECIST 1.1.

    Defined as the proportion of patients with CR, PR, or stable disease (SD).

    Time frame: 3 years

  4. Objective response rate (ORR) of IN10018+nab-paclitaxel+Tislelizumab as compared to nab-paclitaxel+Tislelizumab in previously-treated solid tumors per investigators based on RECIST 1.1.

    Defined as the proportion of subjects with complete response (CR) or partial response (PR).

    Time frame: 3 years

  5. Overall survival (OS) in IN10018+nab-paclitaxel+Tislelizumab as compared to nab-paclitaxel+Tislelizumab in previously-treated solid tumors.

    Defined as the time from randomization to the date of death due to any cause.

    Time frame: 3 years

  6. Number of patients with adverse event

    The number of participants who experienced AEs is presented.

    Time frame: 3 years

  7. PK: AUC of IN10018 following single dose administration and at steady state

    Area under the concentration-time curve (AUC)

    Time frame: 3 years

  8. PK: Cmax of IN10018 following single dose administration and at steady state

    Maximum concentration (Cmax)

    Time frame: 3 years

  9. PK:Ctrough of IN10018 following single dose administration and at steady state

    Trough concentration (Ctrough)

    Time frame: 3 years

  10. PK:Tmax of IN10018 following single dose administration and at steady state

    Time to Cmax (Tmax)

    Time frame: 3 years

  11. PK:t1/2 of IN10018 following single dose administration and at steady state

    Elimination half-life (t1/2).

    Time frame: 3 years

  12. PK:CL/F of IN10018 following single dose administration and at steady state

    apparent clearance (CL/F)

    Time frame: 3 years

  13. PK:Vd/F of IN10018 following single dose administration and at steady state

    Apparent volume of distribution (Vd/F)

    Time frame: 3 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Dec 2026, 16 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2023
First posted
Aug 8, 2023
StartEst.
Aug 13, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05982522
Lead sponsor
InxMed (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Aug 8, 2023
Start date
Aug 13, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 27, 2026

Study contacts

Jifeng Feng
principal investigator · Jiangsu Province Cancer Hosipital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ifebemtinib

Start the discussion